Recursion Pharmaceuticals, Inc. (RXRX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 7.70 |
| Open | 8.15 |
| Bid | 7.93 x 500 |
| Ask | 7.96 x 1400 |
| Day's range | 7.89 - 8.27 |
| 52-week range | 4.54 - 16.75 |
| Volume | |
| Avg. volume | 6,391,280 |
| Market cap | 1.886B |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.58 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
ZacksRecursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) closed at $7.47 in the latest trading session, marking a -1.32% move from the prior day.
GlobeNewswireRecursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors Photo of Najat Khan, Ph.D. Najat Khan, Ph.D. SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief
GuruFocus.comRecursion Pharmaceuticals Inc Director Blake Borgeson Sells 11,447 Shares
On April 2, 2024, Blake Borgeson, Director of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 11,447 shares of the company.
© 2024 Yahoo. All rights reserved.